|
|
Market Analysis Reports of Duocarmycin SA
|
Global Market Report of Duocarmycin SA (CAS 130288-24-3)
December 2024
Global Market Report of Duocarmycin A (CAS 118292-34-5)
December 2024
ADC Payload / Warheads Market: Distribution by Type of Product (Commercialized ADCs and Clinical ADCs), Type of Payload (Microtubule Inhibitors, DNA Damaging Agents, Topoisomerase Inhibitors and Others), Payload / Warhead (Auristatins, Calicheamicin, Camptothecin, Duocarmycin, Maytansinoids, Pyrrolobenzodiazepines and Others) and Geography (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2035
... Payload / Warhead (Auristatins, Calicheamicin, Camptothecin, Duocarmycin, Maytansinoids, Pyrrolobenzodiazepines and Others) ... Payload / Warhead Auristatins Calicheamicin Camptothecin Duocarmycin Maytansinoids Pyrrolobenzodiazepines Others Geographical ...
Antibody Drug Conjugate Market (7th Edition), 2023-2035: Distribution by Target Disease Indication (Breast Cancer, B-cell Lymphoma, Lung Cancer, Multiple Myeloma, Acute Lymphoblastic Leukemia, Gastric Cancer, Renal Cancer, Cervical Cancer and Other Target Disease Indications), Therapeutic Area (Hematological Cancer and Solid Tumor), Linker (Valine-Citrulline, Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate, Tetrapeptide-based Linker, Maleimide, Maleimidocaproyl, Valine-Alanine, Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (AcBut) and Other Linkers), Payload (Monomethyl Auristatin E, DM1, Duocarmycin, SN-38 / Irinotecan, Monomethyl Auristatin F, SG3199, Ozogamicin, DM4 and Other Payloads), Target Antigens (HER-2 (ERBB2), CD79b, Trop-2, BCMA (TNFRSF17 / BCM), CD19, CD22, Tissue Factor, CD30, CEACAM5, Nectin 4 and Others) And Key Geographical Regions (North America (US, Canada), Europe (Germany, UK, France, Italy, Spain), and Asia-Pacific (China, Australia, Japan)): Industry Trends and Global Forecasts
The global antibody drug conjugate market is expected to reach USD 7.72 billion by 2023 and is anticipated to grow at a CAGR of 9.63% during the forecast period 2023-2035 Antibody drug conjugates (ADCs) are a class of engineered therapeutics that combine ...
Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis
Antibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis The report entitledAntibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis published in January 2014 is based on the evaluation of more than 90 companies. The ...
Pancreatic Ductal Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
... treatment candidate is an antibody-drug combination duocarmycin-based linker payload that targets ...
Competitor Analysis: Antibody-Drug Conjugates (ADC)
Product description The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated via a linker with a drug payload for treatment ...
|
|
|
|
